Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes
Avtorji:ID Battelino, Tadej (Avtor)
ID Lalić, Nebojsa M. (Avtor)
ID Hussain, Sufyan (Avtor)
ID Ceriello, Antonio (Avtor)
ID Klobučar, Sanja (Avtor)
ID Davies, Sarah J (Avtor)
ID Topsever, Pinar (Avtor)
ID Heverly, Julie (Avtor)
ID Ulivi, Francesca (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (849,80 KB)
MD5: 18AE24CDE697E16A10868162AD0F42A5
 
URL URL - Izvorni URL, za dostop obiščite https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00125-1/fulltext
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:A global trend towards increased obesity, intermediate hyperglycemia (previously termed prediabetes) and type 2 diabetes, has prompted a range of international initiatives to proactively raise awareness and provide action-driven recommendations to prevent and manage these linked disease states. One approach, that has shown success in managing people already diagnosed with type 2 diabetes mellitus, is to use continuous glucose monitoring (CGM) devices to help them manage their chronic condition through understanding and treating their daily glucose fluctuations, in assocation with glucose-lowering medications, including insulin. However, much of the burden of type 2 diabetes mellitus is founded in the delayed detection both of type 2 diabetes mellitus itself, and the intermediate hyperglycemia that precedes it. In this review, we provide evidence that using CGM technology in people at-risk of intermediate hyperglycemia or type 2 diabetes mellitus can significantly improve the rate and timing of detection of dysglycemia. Earlier detection allows intervention, including through continued use of CGM to guide changes to diet and lifestyle, that can delay or prevent harmful progression of early dysglycemia. Although further research is needed to fully understand the cost-effectiveness of this intervention in people at-risk or with early dysglycemia, the proposition for use of CGM technology is clear.
Ključne besede:continuous glucose monitoring, consensus statements, intermediate hyperglycemia, obesity, prediabetes
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:str. 1-12
Številčenje:Vol. 223
PID:20.500.12556/DiRROS-24592 Novo okno
UDK:616.379
ISSN pri članku:1872-8227
DOI:10.1016/j.diabres.2025.112111 Novo okno
COBISS.SI-ID:250818563 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 29. 9. 2025;
Datum objave v DiRROS:08.12.2025
Število ogledov:89
Število prenosov:40
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Diabetes research and clinical practice
Založnik:Elsevier
ISSN:1872-8227
COBISS.SI-ID:23224837 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0343-2022
Naslov:Etiologija, zgodnje odkrivanje in zdravljenje bolezni pri otrocih in mladostnikih

Financer:UKRI - UK Research and Innovation
Številka projekta:MR/W030004/1
Naslov:Using mesenchymal stromal cell secretory products to improve human islet transplantation.

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.

Nazaj